LB Pharmaceuticals Inc Common Stock
$27.40+0.48%(+$0.13)
TickerSpark Score
61/100
67
Valuation
20
Profitability
60
Growth
100
Health
60
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LBRX research report →
52-Week Range70% of range
Low $13.36
Current $27.40
High $33.47
Companylbpharma.us
Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e. g. schizophrenia, bipolar depression).
- CEO
- Heather D. Turner
- IPO
- 2025
- Employees
- 16
- HQ
- New York, NY, US
Price Chart
+59.13% · this period
Valuation
- Market Cap
- $785.74M
- P/E
- -19.83
- P/S
- 0.00
- P/B
- 2.05
- EV/EBITDA
- -10.21
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -17.68%
- ROIC
- -12.23%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-25,205,000 · 60.06%
- EPS
- $-1.00 · 94.39%
- Op Income
- $-30,404,000
- FCF YoY
- 34.49%
Performance & Tape
- 52W High
- $33.47
- 52W Low
- $13.36
- 50D MA
- $27.90
- 200D MA
- $21.69
- Beta
- 1.38
- Avg Volume
- 251.16K
Get TickerSpark's AI analysis on LBRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Start Free Trial →Our LBRX Coverage
We haven't published any research on LBRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LBRX Report →